Analysts’ Perspective: Dicerna Pharmaceuticals (DRNA), Kosmos Energy (KOS), Square (SQ)

Investment Analysts at B. Riley FBR upgrade Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) shares from Neutral to Buy rating while increasing their price target from $13.50 to $21.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases.


Brokerage Firm Goldman upgraded Kosmos Energy Ltd (NYSE:KOS) shares from Neutral to Buy rating.

Kosmos Energy Ltd. explores for and produces oil and gas in Africa and South America.


Square, Inc. (NYSE:SQ) shares were upgraded by analysts at Citigroup from Neutral to Buy rating.

Square, Inc. provides payment and point-of-sale solutions in the United States and internationally.


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE.Info is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at